• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Gossamer Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/15/25 4:02:16 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GOSS alert in real time by email
    goss-20250515
    0001728117FALSE00017281172025-05-152025-05-15

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): May 15, 2025
    GOSSAMER BIO, INC.
    (Exact name of Registrant as Specified in Its Charter)
     
    Delaware001-3879647-5461709
    (State or Other Jurisdiction
    of Incorporation)
    (Commission File Number)(IRS Employer
    Identification No.)
       
    3115 Merryfield Row, Suite 120
    San Diego, California, 92121

    (Address of Principal Executive Offices) (Zip Code)
    (858) 684-1300
    (Registrant’s Telephone Number, Including Area Code)
    N/A
    (Former Name or Former Address, if Changed Since Last Report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class Trading
    Symbol(s)
     Name of each exchange on which registered
    Common Stock, $0.0001 par value per share GOSS Nasdaq Global Select Market
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐



    Item 2.02 Results of Operations and Financial Condition.
    On May 15, 2025, Gossamer Bio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2025. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
    In accordance with General Instruction B.2 of Form 8-K, the information contained or incorporated herein, including the press release attached as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
    Item 9.01 Financial Statements and Exhibits.
    (d) Exhibits.
     
    Exhibit
    Number
     Description
    99.1 
    Press Release dated May 15, 2025
     101  Cover Page Interactive Data File (embedded within the Inline XBRL document)
    1


    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
     
      GOSSAMER BIO, INC.
        
    Date: May 15, 2025
     By:/s/ Bryan Giraudo
       Bryan Giraudo
       Chief Financial Officer and Chief Operating Officer

    2
    Get the next $GOSS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GOSS

    DatePrice TargetRatingAnalyst
    6/25/2024$9.00Outperform
    Oppenheimer
    4/5/2024$4.00Outperform
    Wedbush
    7/27/2023$8.00 → $1.25Buy → Neutral
    UBS
    3/7/2023Outperform → Mkt Perform
    Raymond James
    3/1/2023Neutral
    Guggenheim
    12/7/2022Neutral → Underweight
    JP Morgan
    12/7/2022$3.00Outperform → Neutral
    SMBC Nikko
    12/7/2022$18.00 → $2.00Overweight → Equal Weight
    Barclays
    More analyst ratings

    $GOSS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

      - Enrollment Completion for Ongoing Registrational PROSERA Phase 3 Study in PAH Expected in Early June; New Patient Screening Closed - - Topline Results Announcement from PROSERA Phase 3 Expected in February 2026 - - To Date, Blinded Baseline Characteristics Align with Intended Study Population - - First Site Activations for Planned Registrational Phase 3 SERANATA Study in PH-ILD Expected in the Fourth Quarter of 2025 - - Cash, cash equivalents and marketable securities totaled $258 million as of March 31, 2025 - Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmona

      5/15/25 4:01:00 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025

      Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it will report its first quarter 2025 financial results on Thursday, May 15, 2025. In connection with the earnings release, Gossamer's management team will host a live conference call and webcast at 4:30 p.m. ET on Thursday, May 15, 2025, to discuss the Company's financial results and provide a corporate update. Domestic Dial-in Number: (800) 285-6670 International Dial-in Number: (713) 4

      5/12/25 4:01:00 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective May 5, 2025, to three non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 258,750 shares of the Company's common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan ("2023 Inducement Plan"). The awards were granted as an induceme

      5/7/25 5:30:00 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOSS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Gossamer Bio with a new price target

      Oppenheimer initiated coverage of Gossamer Bio with a rating of Outperform and set a new price target of $9.00

      6/25/24 7:48:05 AM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush resumed coverage on Gossamer Bio with a new price target

      Wedbush resumed coverage of Gossamer Bio with a rating of Outperform and set a new price target of $4.00

      4/5/24 7:26:48 AM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gossamer Bio downgraded by UBS with a new price target

      UBS downgraded Gossamer Bio from Buy to Neutral and set a new price target of $1.25 from $8.00 previously

      7/27/23 9:01:18 AM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOSS
    Financials

    Live finance-specific insights

    See more
    • Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

      - Enrollment Completion for Ongoing Registrational PROSERA Phase 3 Study in PAH Expected in Early June; New Patient Screening Closed - - Topline Results Announcement from PROSERA Phase 3 Expected in February 2026 - - To Date, Blinded Baseline Characteristics Align with Intended Study Population - - First Site Activations for Planned Registrational Phase 3 SERANATA Study in PH-ILD Expected in the Fourth Quarter of 2025 - - Cash, cash equivalents and marketable securities totaled $258 million as of March 31, 2025 - Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmona

      5/15/25 4:01:00 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025

      Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it will report its first quarter 2025 financial results on Thursday, May 15, 2025. In connection with the earnings release, Gossamer's management team will host a live conference call and webcast at 4:30 p.m. ET on Thursday, May 15, 2025, to discuss the Company's financial results and provide a corporate update. Domestic Dial-in Number: (800) 285-6670 International Dial-in Number: (713) 4

      5/12/25 4:01:00 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

      - PROSERA Phase 3 in PAH on Track for Topline Data Readout in Fourth Quarter of 2025 - - Registrational Phase 3 in PH-ILD Expected to Commence in Second Half of 2025 - - Seralutinib Receives Orphan Drug Designation for PAH in Japan - - Cash, cash equivalents and marketable securities totaled $295 million at year-end 2024 - Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter and year ended December

      3/13/25 4:01:00 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by EVP, Regulatory Affairs Peterson Caryn

      4 - Gossamer Bio, Inc. (0001728117) (Issuer)

      3/6/25 4:09:17 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by EVP, Tech Ops and Admin Christian Waage

      4 - Gossamer Bio, Inc. (0001728117) (Issuer)

      3/6/25 4:08:00 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Commercial Officer Smith Robert Paul Jr

      4 - Gossamer Bio, Inc. (0001728117) (Issuer)

      3/6/25 4:06:46 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOSS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

      SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

      11/12/24 4:40:26 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

      SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

      11/12/24 9:55:14 AM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Gossamer Bio Inc.

      SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)

      8/2/24 6:30:57 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOSS
    SEC Filings

    See more
    • Gossamer Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Gossamer Bio, Inc. (0001728117) (Filer)

      5/15/25 4:02:16 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Gossamer Bio Inc.

      10-Q - Gossamer Bio, Inc. (0001728117) (Filer)

      5/15/25 4:01:31 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Gossamer Bio Inc.

      DEFA14A - Gossamer Bio, Inc. (0001728117) (Filer)

      4/29/25 4:01:51 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOSS
    Insider purchases explained

    Analytical look into recent insider purchases

    See more

    $GOSS
    Leadership Updates

    Live Leadership Updates

    See more
    • Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

      Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

      6/21/24 3:17:31 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

      - Mr. Smith is a recognized leader in the commercialization of PAH products, most recently leading sotatercept US pre-launch activities at Merck - - Previously, Mr. Smith led US sales operations for Actelion - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of Bob Smith as its Chief Commercial Officer. "We are proud to welcome Bob Smith to the Gossamer team and his 30 years of expertise at this critical time in our company's history," said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio.

      12/5/23 7:01:00 AM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors

      Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of John Quisel, J.D., Ph.D., President and CEO of Disc Medicine, to its Board of Directors. "Today, we are thrilled to announce that Dr. John Quisel has joined the Gossamer team," said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio. "Not only is Dr. Quisel a recognized industry leader with a proven track record of success, but he also brings unique strategic insights and experience in PAH, which will be invaluable. We are confident that Dr. Quise

      11/29/23 7:01:00 AM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs

      Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that Rainer Zimmermann, MD, has joined the Company as Vice President of Medical Affairs. Dr. Zimmermann brings more than 23 years of experience within the PAH/PH space, most recently having served as the Global Medical Lead, Medical Affairs, Pulmonary Hypertension, at Johnson & Johnson Innovative Medicine. In this role, he partnered with the development and commercial teams to lead pre-launch and launch activities of several approved PAH products, including Uptravi® (selixpag),

      10/3/23 4:08:00 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOSS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Hasnain Faheem bought $250,282 worth of shares (372,000 units at $0.67) (SEC Form 4)

      4 - Gossamer Bio, Inc. (0001728117) (Issuer)

      6/24/24 5:52:18 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • COO/CFO Giraudo Bryan bought $59,110 worth of shares (100,000 units at $0.59) (SEC Form 4)

      4 - Gossamer Bio, Inc. (0001728117) (Issuer)

      6/20/24 8:21:38 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Commercial Officer Smith Robert Paul Jr bought $15,050 worth of shares (25,000 units at $0.60) (SEC Form 4)

      4 - Gossamer Bio, Inc. (0001728117) (Issuer)

      6/20/24 8:20:20 PM ET
      $GOSS
      Biotechnology: Pharmaceutical Preparations
      Health Care